Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO
Read the original post:
Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at...
Dr. James Woody’s leadership qualities and experience leading innovative pharmaceutical ventures and raising funds will power Enosi’s development of second-generation anti-TNF therapeutics for inflammatory autoimmune diseases and cancer.
FORT LAUDERDALE, Fla., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that the China National Intellectual Property Administration ("CNIPA") issued patent 201680002365, titled “Distal Front End for Coordination Positioning of an Endoscope with a Suction Device.” The patent covers the method of mounting Motus GI’s proprietary sensing technology and enhanced suction systems with the distal end of a colonoscope. This patent further protects the Company’s flagship product – the Pure-Vu® System – in this key potential market.
Continue reading here:
Motus GI Expands Intellectual Property Portfolio with Chinese Patent for its Method to Mount the Pure-Vu® System on the End of a Colonoscope
MENLO PARK, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced the appointment of Susan G. Kim as Chief Financial Officer, effective as of September 28, 2020.
Read this article:
Pacific Biosciences Announces New Chief Financial Officer
PRESS RELEASE
Read the original here:
Saniona announces outcome of warrant exercise
WEST CHESTER, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that positive results from the two pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients [CAMP-1 and CAMP-2]) studies evaluating the safety and efficacy of VP-102 in children and adults with molluscum were published in the Journal of the American Medical Association (JAMA) Dermatology.
See more here:
JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials
BASKING RIDGE, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, chief executive officer, will participate in a fireside chat at the JMP Securities MedTech Bio Summit, which is being held virtually October 1-2, 2020.
Excerpt from:
electroCore to Participate in the JMP Securities MedTech Bio Summit